This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Fibroblast growth factor receptor 1 (FGFR1; CD331); fibroblast growth factor 21 (FGF21)	<p>A study in mice suggests an agonist mAb of FGFR1 could help treat type 2 diabetes. In a mouse model of diabetes, an agonistic mAb that mimics the effect of FGF21 decreased blood glucose, insulin and lipid levels as effectively as recombinant FGF21 while having a longer half-life and duration of action. Next steps include optimization and further preclinical development of the FGFR1 mAb as a type 2 diabetes candidate. Ambrx Inc. and Bristol-Myers Squibb Co. have ARX618, a stabilized form of FGF21, in preclinical development for type 2 diabetes.</p> <p>SciBX 5(3); doi:10.1038/scibx.2012.72 Published online Jan. 19, 2012</p>	Patent pending; unavailable for licensing	<p>Wu, A.L. <i>et al. Sci. Transl. Med.</i>; published online Dec. 14, 2011; doi:10.1126/scitranslmed.3002669 Contact: Junichiro Sonoda, Genentech Inc., South San Francisco, Calif. e-mail: junichis@gene.com</p>